Related Experiment Video
Updated: Jul 23, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate
W P Hausdorff1, J Bryant, C Kloek
1Wyeth-Lederle Vaccines, West Henrietta and Pearl River, NY 14586, USA. Hausdowp@war.wyeth.com
Abstract:
To assess whether certain serogroups of Streptococcus pneumoniae are preferentially associated with specific disease manifestations, we analyzed all recent pneumococcal disease studies and assessed the relative frequency of isolation of each serogroup by clinical site (as a proxy for different disease states). In all age groups, serogroups 1 and 14 were more often isolated from blood, and serogroups 6, 10, and 23 were more often isolated from cerebrospinal fluid (CSF); in young children, serogroups 3, 19, and 23 were more often isolated from middle ear fluid (MEF). Serogroups represented in conjugate vaccines were isolated slightly less frequently from CSF than from blood or MEF. Nonetheless, serogroups in the 9-valent conjugate vaccine formulation still comprised approximately 75% of pneumococcal isolates from the CSF of young children in Europe and in the United States and Canada. These analyses indicate that pneumococcal conjugate vaccines could potentially prevent a substantial proportion of episodes of bacteremic disease, pneumonia, meningitis, and otitis media, especially in young children.
Insights
Certain Streptococcus pneumoniae serogroups are linked to specific diseases like meningitis and otitis media. Pneumococcal conjugate vaccines show potential in preventing these serious infections, particularly in young children.
Area of Science:
- Microbiology
- Infectious Diseases
- Vaccinology
Background:
- Streptococcus pneumoniae causes significant global disease burden.
- Understanding serogroup distribution in different infections is crucial for vaccine development.
Purpose of the Study:
- To determine if specific pneumococcal serogroups are preferentially associated with distinct clinical manifestations.
- To evaluate the potential impact of pneumococcal conjugate vaccines on disease prevention.
Main Methods:
- Analysis of recent pneumococcal disease studies.
- Assessment of serogroup isolation frequency by clinical site as a proxy for disease state.
- Comparison of serogroup prevalence in blood, cerebrospinal fluid (CSF), and middle ear fluid (MEF).
Main Results:
- Serogroups 1 and 14 were more frequent in blood isolates.
- Serogroups 6, 10, and 23 were more frequent in CSF isolates.
- Serogroups 3, 19, and 23 were more frequent in MEF isolates from young children.
- Vaccine-represented serogroups were less frequent in CSF compared to blood or MEF.
- Vaccine serogroups constituted approximately 75% of pediatric CSF isolates in Europe and North America.
Conclusions:
- Pneumococcal serogroup distribution varies by disease site.
- Pneumococcal conjugate vaccines could prevent a substantial proportion of invasive pneumococcal disease, pneumonia, meningitis, and otitis media.
- Vaccine impact is particularly significant in young children.
Related Concept Videos
01:51Vaccinations
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:30Pneumonia III: Complications and Assessment
01:26Bacterial Meningitis II: Pathophysiology
01:29Pneumonia I: Introduction